hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 05:39:06 - browse：5

BIO is proceeding with a restructuring after its new CEO took over. Lane Turner/The Boston Globe

WASHINGTON — The Biotechnology Innovation Organization on Monday is announcing a significant restructuring accompanied by a shakeup, according to five sources familiar with the planning.

A few senior leaders are expected to depart as part of the reorganization. Chief Science Officer Cartier Esham, Chief Public Affairs and Marketing Officer Rich Masters, and Chief Policy Officer John Murphy are expected to leave, four sources said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The SUPPORT Act is critical to fighting the opioid crisis

WSS

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Readout LOUD podcast: live from JPM 2024

GSK to buy asthma

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Websites selling Wegovy, Zepbound ingredients targeted by FDA

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

The high cost of giving birth even with insurance

Health and fitness trackers are measuring the wrong things

Psychedelics group wrestles with new pharma identity

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Supreme Court strikes down use of affirmative action

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Medical leaders decry Supreme Court decision on affirmative action

The SUPPORT Act is critical to fighting the opioid crisis

Walensky prepares to leave CDC — and Congress — behind

The nurse manager staffing crisis is hurting patients

entertainment

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Abbott's new heart device gets FDA advisory panel nod

Risky weight loss products often used by teens globally, per study

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Abbott's new heart device gets FDA advisory panel nod

Tome Biosciences co

explore

focus

knowledge

leisure time